Onpattro (patisiran) / Medison, Alnylam, Sanofi, Arbutus  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Onpattro (patisiran) / Alnylam, Sanofi
NCT01559077: Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Completed
1
17
Europe
ALN-TTR02, Sterile Normal Saline (0.9% NaCl)
Alnylam Pharmaceuticals
TTR-mediated Amyloidosis
06/12
11/12
NCT02053454: A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Completed
1
12
Europe
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Alnylam Pharmaceuticals
Transthyretin (TTR)-Mediated Amyloidosis
03/14
06/14
NCT05023889: Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Recruiting
1
10
US
patisiran, ONPATTRO
Austin Neuromuscular Center, Alnylam Pharmaceuticals
Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
10/24
12/24

Download Options